Skip to main content

Table 2 Summary of phenotypic analyses of patient leukocytes

From: Immunological effects of nivolumab immunotherapy in patients with oral cavity squamous cell carcinoma

 

Pre-treatment

Post-treatment

p-value

CD4+ cells (%)

46.9

40.1

0.045

% of CD4+ cells

 IFN-γ +

20.0

23.9

0.225

 Foxp3+

7.7

9.2

0.047

CD8+ cells (%)

25.6

30.1

0.043

% of CD8+ cells

 IFN-γ +

58.0

62.2

0.108

 Granz B+

46.7

55.5

0.101

% of CD8+CD4CD3+ cells

 CD8dimCD3+

10.4

12.2

0.015

 CD8dimCD3

27.4

28.7

0.709

 CD8hiCD3+

61.6

59.1

0.454

% of CD8dimCD3+ cells

 IFN-γ+

60.7

62.9

0.404

 Granzyme B+

34.7

42.6

0.023

% of CD8dimCD3 cells

 IFN-γ+

70.5

68.9

0.572

 Granzyme B+

91.2

91.5

0.853

% of CD8hiCD3+ cells

 IFN-γ+

51.1

57.3

0.054

  Granzyme B+

26.4

36.7

0.009

  1. Peripheral blood leukocytes were collected from OCSCC patients prior to and following treatment with nivolumab. Cells were immunostained flow cytometrically analyzed